MedPath

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia

A 5-year follow-up of the Phase 2 Optic Study reveals insights into the efficacy, safety, and first end-of-treatment mutational results for patients with chronic-phase chronic myeloid leukemia.

The 5-year follow-up of the Phase 2 Optic Study provides comprehensive data on the treatment outcomes for patients with chronic-phase chronic myeloid leukemia (CML). The study, published in the journal Blood in 2024, highlights the efficacy and safety of the treatment regimen over a significant period. It also presents the first end-of-treatment mutational results, offering valuable insights into the genetic changes associated with the disease and its treatment. The research, led by Jorge E. Cortes and a team of international collaborators, underscores the importance of long-term follow-up in understanding the dynamics of CML treatment and its impact on patient outcomes. This study contributes to the growing body of evidence supporting the management of CML, aiming to improve the quality of life and survival rates for patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

LUMEVOQ Gene Therapy Shows Sustained Vision Improvement in LHON Patients After 5 Years

GenSight Biologics' LUMEVOQ demonstrates sustained visual acuity improvement in Leber Hereditary Optic Neuropathy (LHON) patients five years post-treatment.
Bilateral injections of LUMEVOQ resulted in a higher rate of clinically relevant visual recovery compared to unilateral treatment in the REFLECT Phase III trial.

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia

Dr. Jorge E. Cortes presents the 5-year follow-up results from the Phase 2 OPTIC study, highlighting the long-term efficacy, safety, and mutational analysis of ponatinib in treating chronic-phase chronic myeloid leukemia.

MicroPulse TLT Demonstrates Long-Term Efficacy in Glaucoma Management

A 5-year study validates MicroPulse Transscleral Laser Therapy (TLT) as a safe and effective treatment for primary and secondary glaucoma, showcasing sustained IOP reduction.
The research, involving 165 eyes, showed a 32.5% average reduction in intraocular pressure (IOP) and decreased reliance on IOP-lowering medications.

Olverembatinib Shows Promise as Second-Line Therapy for Chronic Phase CML

Olverembatinib demonstrates notable efficacy in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to first-line TKIs.
The study showed that 74.1% of efficacy-evaluable patients achieved complete cytogenetic response (CCyR), and 40.6% experienced major molecular response (MMR).

Nanoscope's MCO-010 Gene Therapy Shows Sustained Vision Improvement in Retinitis Pigmentosa Trial

Nanoscope Therapeutics' MCO-010 gene therapy significantly improved visual acuity in retinitis pigmentosa patients compared to the control group in a Phase 2b trial.
The RESTORE trial demonstrated statistically significant and durable vision improvement over a two-year period, with some patients showing clinically meaningful gains.

Zanubrutinib, Obinutuzumab, and Venetoclax Triplet Achieves High uMRD Rates in CLL/SLL

A phase 2 trial (BOVen) showed that zanubrutinib plus obinutuzumab and venetoclax induced high rates of undetectable minimal residual disease (uMRD) in CLL/SLL patients.
92% of patients achieved uMRD in both peripheral blood and bone marrow, leading to treatment discontinuation after a median of 10 months.

Ponatinib Dose-Ranging Study Shows Efficacy in Chronic-Phase CML Patients

A phase 2 trial evaluating ponatinib in chronic-phase chronic myeloid leukemia (CP-CML) patients resistant to prior tyrosine kinase inhibitors (TKIs) demonstrated significant efficacy across three starting doses. The study highlighted a novel, response-based dose-reduction strategy, with the 45 mg starting dose showing optimal benefit/risk outcomes when reduced to 15 mg upon achieving a response.

Acalabrutinib, Venetoclax, and Obinutuzumab Triplet Shows High Efficacy in CLL

Acalabrutinib, venetoclax, and obinutuzumab (AVO) triplet therapy demonstrates high activity in previously untreated CLL patients, including those with high-risk TP53 aberrations.
The AVO regimen achieved a bone marrow undetectable MRD (BM-uMRD) rate of 78% after 15 months, indicating deep remission in a significant proportion of patients.

Final 5-Year Results of the Phase 2 PACE Trial for CML and Ph+ ALL Patients

The PACE trial's final 5-year results demonstrate ponatinib's efficacy and safety in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have undergone prior therapies. The study highlights significant response rates, durability of responses, and the impact of dose adjustments on maintaining efficacy while managing adverse events.

Phase 2 Trial Shows High Efficacy of BOVen Regimen in Treating Chronic Lymphocytic Leukaemia

A phase 2 trial investigating the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) for treating chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) has shown promising results, with 89% of patients achieving undetectable minimal residual disease (MRD) in both peripheral blood and bone marrow. The study highlights the regimen's safety and efficacy, suggesting a potential new standard for first-line therapy in CLL/SLL patients.

Reference News

[1]
5-Year Follow-up of the Phase 2 Optic Study in Patients ...
semanticscholar.org · Nov 5, 2024

5-year follow-up of the Phase 2 Optic Study shows efficacy and safety in chronic-phase CML patients, including first end...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy